ANI Pharmaceuticals is expected to report Q3 2026 revenue of $280.26 million and adjusted EPS of $2.18, with shares currently trading at $72.23 against a $105.78 average analyst price target.
Investors are primarily focused on Cortrophin Gel's sales momentum as the company pivots toward a higher-margin Rare Disease portfolio. Management recently narrowed the full-year Cortrophin guidance to $520–$540 million, making second-half execution a critical barometer for growth.
Beyond Cortrophin, markets are evaluating the early traction of the newly expanded gout sales force and the integration of Alimera Sciences. Steady performance in the core generics business remains essential to fund these specialty expansion efforts.